Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02969876 · ClinicalTrials.gov registry record · Phase 4
Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT02969876: Clinical Trial Phase 4 study, sponsored by Massachusetts General Hospital.
NCT02969876 is a Phase 4 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02969876, a Phase 4 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
The study is a 6-week, proof-of-concept, open trial of vortioxetine for 20 patients with major depressive disorder.
Interventions
- DRUG Vortioxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-08-24 |
| Est. Completion | 2018-08-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02969876
The ClinicalTrials.gov registry entry for NCT02969876 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vortioxetine is the first listed.
NCT02969876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02969876 about?
NCT02969876 is a clinical study titled "Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine". The study is a 6-week, proof-of-concept, open trial of vortioxetine for 20 patients with major depressive disorder.
What is the current status of trial NCT02969876?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2017-08-24. Estimated completion is 2018-08-06.
What interventions are being tested in trial NCT02969876?
The interventions under investigation include: Vortioxetine (DRUG).
Who is sponsoring clinical trial NCT02969876?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.